8,9-EET analogs protect glomerular cells from doxorubicin-induced toxicity
Abstract
IntroductionDoxorubicin (DOX) is an anthracycline chemotherapeutic whose clinical utility is limited by dose-dependent nephrotoxicity that contributes to acute and chronic kidney injury. Podocytes are essential components of the glomerular filtration barrier and are particularly vulnerable to DOX-induced oxidative stress, cytoskeletal disruption, loss of adhesion, and apoptosis. Therapeutic strategies that protect podocytes without compromising anticancer efficacy therefore represent an important unmet need. This study investigated the protective mechanisms and translational potential of 8,9-epoxyeicosatrienoic acid (8,9-EET) analogs against DOX-induced podocyte injury.MethodsNineteen 8,9-EET analogs were screened in cultured podocytes exposed to DOX. Protective effects were evaluated by assessing cell viability, caspase-3/7 activation, reactive oxygen species (ROS) generation, and focal adhesion integrity using confocal immunofluorescence analysis of vinculin. Selected analogs were also evaluated in DU145 prostate cancer and HCC1806 breast cancer cells to determine whether podocyte protection altered the anticancer activity of DOX.Results and DiscussionSeveral 8,9-EET analogs significantly improved podocyte viability and attenuated DOX-induced apoptosis, as demonstrated by reduced caspase-3/7 activation. DOX markedly disrupted focal adhesion complexes, decreasing vinculin number and area, whereas co-treatment with selected analogs preserved vinculin-associated focal adhesion integrity. Effective analogs also significantly reduced DOX-induced ROS generation, consistent with attenuation of oxidative stress. Importantly, selected analogs protected podocytes without compromising DOX anticancer activity in either DU145 or HCC1806 cells, supporting separation of renoprotective effects from the desired cytotoxic action of DOX. These findings identify selected 8,9-EET analogs as promising podocyte-protective agents against DOX-induced injury. Their protective effects were associated with reduced oxidative stress and apoptosis and preservation of focal adhesion architecture, suggesting coordinated maintenance of podocyte structural integrity and survival. Preservation of DOX anticancer activity in prostate and breast cancer cells further supports the translational potential of these compounds as adjunctive therapies during anthracycline chemotherapy. Collectively, targeting epoxy lipid signaling with 8,9-EET analogs may provide a strategy to limit chemotherapy-associated podocyte injury and preserve renal function without diminishing antitumor efficacy. These results support preclinical evaluation of lead analogs, including their pharmacological properties, renal protective efficacy, and therapeutic compatibility with DOX in relevant models. These findings warrant defining efficacy, safety, dosing, and translational feasibility in vivo.
Related
- Immuno-oxidative biomarkers and histopathological evaluation of heart and spleen tissues in doxorubicin- and cisplatin-induced toxicity in male albino rats
- Ataxin-2 downregulation rewires neuronal and astrocytic metabolism to protect against TDP-43 toxicity
- Empagliflozin does not rescue nor exacerbate doxorubicin-induced skeletal muscle wasting and metabolic dysfunction in male mice
- Extracellular vesicle-encapsulated GDF15 alleviates doxorubicin-induced cardiotoxicity via the SUB1/TERT/TPP signalling axis
- Nintedanib-induced Glomerular Microangiopathy after Long-term Nintedanib Administration Presenting with Nephrotic Syndrome
BibTeX
@article{weldemichael202689eet,
title = {{8,9-EET analogs protect glomerular cells from doxorubicin-induced toxicity}},
author = {Tsigereda Weldemichael and Md. Abdul Hye Khan and Yahaya Adams and Abhishek Mishra and Samaneh Goorani and Anders Vik and Darin E. Jones and John D. Imig},
journal = {Frontiers in Pharmacology},
year = {2026},
month = nov,
doi = {10.3389/fphar.2026.1913312},
url = {https://www.frontiersin.org/articles/10.3389/fphar.2026.1913312},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - 8,9-EET analogs protect glomerular cells from doxorubicin-induced toxicity
AU - Tsigereda Weldemichael
AU - Md. Abdul Hye Khan
AU - Yahaya Adams
AU - Abhishek Mishra
AU - Samaneh Goorani
AU - Anders Vik
AU - Darin E. Jones
AU - John D. Imig
PY - 2026
DA - 2026/11/02
JO - Frontiers in Pharmacology
DO - 10.3389/fphar.2026.1913312
UR - https://www.frontiersin.org/articles/10.3389/fphar.2026.1913312
AB - IntroductionDoxorubicin (DOX) is an anthracycline chemotherapeutic whose clinical utility is limited by dose-dependent nephrotoxicity that contributes to acute and chronic kidney injury. Podocytes are essential components of the glomerular filtration barrier and are particularly vulnerable to DOX-induced oxidative stress, cytoskeletal disruption, loss of adhesion, and apoptosis. Therapeutic strategies that protect podocytes without compromising anticancer efficacy therefore represent an important unmet need. This study investigated the protective mechanisms and translational potential of 8,9-epoxyeicosatrienoic acid (8,9-EET) analogs against DOX-induced podocyte injury.MethodsNineteen 8,9-EET analogs were screened in cultured podocytes exposed to DOX. Protective effects were evaluated by assessing cell viability, caspase-3/7 activation, reactive oxygen species (ROS) generation, and focal adhesion integrity using confocal immunofluorescence analysis of vinculin. Selected analogs were also evaluated in DU145 prostate cancer and HCC1806 breast cancer cells to determine whether podocyte protection altered the anticancer activity of DOX.Results and DiscussionSeveral 8,9-EET analogs significantly improved podocyte viability and attenuated DOX-induced apoptosis, as demonstrated by reduced caspase-3/7 activation. DOX markedly disrupted focal adhesion complexes, decreasing vinculin number and area, whereas co-treatment with selected analogs preserved vinculin-associated focal adhesion integrity. Effective analogs also significantly reduced DOX-induced ROS generation, consistent with attenuation of oxidative stress. Importantly, selected analogs protected podocytes without compromising DOX anticancer activity in either DU145 or HCC1806 cells, supporting separation of renoprotective effects from the desired cytotoxic action of DOX. These findings identify selected 8,9-EET analogs as promising podocyte-protective agents against DOX-induced injury. Their protective effects were associated with reduced oxidative stress and apoptosis and preservation of focal adhesion architecture, suggesting coordinated maintenance of podocyte structural integrity and survival. Preservation of DOX anticancer activity in prostate and breast cancer cells further supports the translational potential of these compounds as adjunctive therapies during anthracycline chemotherapy. Collectively, targeting epoxy lipid signaling with 8,9-EET analogs may provide a strategy to limit chemotherapy-associated podocyte injury and preserve renal function without diminishing antitumor efficacy. These results support preclinical evaluation of lead analogs, including their pharmacological properties, renal protective efficacy, and therapeutic compatibility with DOX in relevant models. These findings warrant defining efficacy, safety, dosing, and translational feasibility in vivo.
SN - 1663-9812
ER -